An Open-label, Single-arm, Post- Authorization Pragmatic Clinical Trial On The Safety And Efficacy Of Xyntha (Moroctocog-alfa (Af-cc), Recombinant Fviii) In Subjects With Hemophilia A In Usual Care Settings In China
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Moroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Pfizer
- 07 Sep 2016 Status changed from active, no longer recruiting to completed.
- 09 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2016 Planned End Date changed from 1 Sep 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov record.